Free Trial
NASDAQ:MTEM

Molecular Templates (MTEM) Stock Price, News & Analysis

Molecular Templates logo
$0.0001 0.00 (-50.00%)
As of 03:16 PM Eastern

About Molecular Templates Stock (NASDAQ:MTEM)

Key Stats

Today's Range
$0.0001
$0.0001
50-Day Range
N/A
52-Week Range
$0.00
$2.04
Volume
207 shs
Average Volume
4.04 million shs
Market Capitalization
$658.40
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

Remove Ads

Molecular Templates Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
20th Percentile Overall Score

MTEM MarketRank™: 

Molecular Templates scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Molecular Templates.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Molecular Templates is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Molecular Templates is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Molecular Templates has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Molecular Templates' valuation and earnings.
  • Short Interest

    There is no current short interest data available for MTEM.
  • Dividend Yield

    Molecular Templates does not currently pay a dividend.

  • Dividend Growth

    Molecular Templates does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for MTEM.
  • Search Interest

    1 people have searched for MTEM on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Molecular Templates insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.90% of the stock of Molecular Templates is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    95.47% of the stock of Molecular Templates is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Molecular Templates' insider trading history.
Receive MTEM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Molecular Templates and its competitors with MarketBeat's FREE daily newsletter.

MTEM Stock News Headlines

Nasdaq to file Form 25-NSE with SEC to delist Molecular Templates
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
Molecular Templates Announces Key Leadership Transition
See More Headlines

MTEM Stock Analysis - Frequently Asked Questions

Molecular Templates' stock was trading at $0.04 at the beginning of 2025. Since then, MTEM stock has decreased by 99.8% and is now trading at $0.0001.
View the best growth stocks for 2025 here
.

Molecular Templates, Inc. (NASDAQ:MTEM) posted its quarterly earnings results on Monday, November, 15th. The biotechnology company reported ($8.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.67) by $2.43. The biotechnology company had revenue of $2.38 million for the quarter, compared to the consensus estimate of $15.69 million. Molecular Templates had a negative trailing twelve-month return on equity of 260.50% and a negative net margin of 61.35%.

Molecular Templates shares reverse split on Monday, August 14th 2023. The 1-15 reverse split was announced on Friday, August 11th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of MTEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Molecular Templates investors own include NVIDIA (NVDA), Meta Platforms (META), General Electric (GE), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Alibaba Group (BABA) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

Last Earnings
11/15/2021
Today
4/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MTEM
Employees
260
Year Founded
2009

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-8,120,000.00
Pretax Margin
-61.39%

Debt

Sales & Book Value

Annual Sales
$23.48 million
Price / Cash Flow
N/A
Book Value
$0.78 per share
Price / Book
0.00

Miscellaneous

Free Float
5,669,000
Market Cap
$658.40
Optionable
No Data
Beta
1.22

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:MTEM) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners